Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 14/20 | 0.67 |
| ▸ | INSR | P06213 | 7/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.67 |
| ▸ | NPM1 | P06748 | 4/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
| ▸ | TTK | P33981 | 3/20 | 0.62 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.56 |
| ▸ | IGF1R | P08069 | 2/20 | 0.53 |
| ▸ | GRK2 | P25098 | 1/20 | 0.53 |
| ▸ | GRK5 | P34947 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1545917 | 0.92 | ALK (0.79) | ALKINSRKCNH2NPM1CYP3A4 | |
| SCHEMBL1546097 | 0.89 | ALK (0.85) | ALKINSRKCNH2NPM1CYP3A4 | |
| SCHEMBL1546353 | 0.88 | ALK (0.64) | ALKINSRKCNH2NPM1CYP3A4 | |
| SCHEMBL1545693 | 0.85 | ALK (0.82) | ALKINSRKCNH2NPM1CYP3A4 | |
| SCHEMBL1546296 | 0.85 | ALK (0.82) | ALKINSRKCNH2 | |
| SCHEMBL12388962 | 0.85 | ALK (0.69) | ALKINSRKCNH2NPM1CYP3A4 | |
| SCHEMBL1545746 | 0.83 | ALK (0.77) | ALKINSRKCNH2NPM1CYP3A4 | |
| SCHEMBL12388945 | 0.83 | ALK (0.75) | ALKINSRKCNH2NPM1CYP3A4 | |
| SCHEMBL12388987 | 0.82 | ALK (0.56) | ALKINSRKCNH2NPM1CYP3A4 | |
| SCHEMBL1545915 | 0.82 | ALK (0.81) | ALKINSRKCNH2NPM1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957081-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2015-02-17 | — | — | US | disclosed |
| US-8957081-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2015-02-17 | — | — | US | disclosed |
| US-20130005748-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2013-01-03 | — | — | US | disclosed |
| US-20130005748-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2013-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005748-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ZAP70, IGF1R, PTK2 | ALK 23/4885INSR 67/4885KCNH2 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.